Dr. Sandra P. D'Angelo

Dr. Sandra P. D'Angelo, MD, is a medical oncologist specializing in the care of patients with soft tissue sarcomas, bone sarcomas, and Merkel cell carcinoma at Memorial Sloan Kettering Cancer Center. She works closely with a multidisciplinary team of medical oncologists, surgeons, radiation oncologists, nurses, and patient support advocates to provide comprehensive care for patients with these rare diseases. Her approach to patient care centers on partnership and empowerment, ensuring that individuals facing these challenging diagnoses receive optimal, personalized treatment at every step.

Dr. D'Angelo is a leading investigator in the use of immunotherapy for sarcoma treatment. She has designed and conducted numerous clinical trials of investigational therapies that harness the body's immune system to fight multiple types of sarcoma, including trials of immune checkpoint inhibitors that have demonstrated effectiveness in specific subtypes such as undifferentiated pleomorphic sarcoma, angiosarcoma, and dedifferentiated liposarcoma. She has also led clinical trials studying T cells engineered to recognize specific molecules on synovial sarcomas and myxoid round cell liposarcomas, advancing a new frontier in targeted cellular therapy for these difficult-to-treat cancers.

Her translational research focuses on identifying biomarkers that can predict which patients are most likely to benefit from systemic immunotherapy. By bridging laboratory discoveries with clinical application, Dr. D'Angelo and her team at MSK have contributed meaningfully to the field of sarcoma immunotherapy and continue to push the boundaries of what is possible for patients with these rare malignancies. Her work reflects a deep commitment to improving outcomes through scientific innovation, collaborative care, and a patient-centered philosophy.